New triple drug combo could beat malaria resistance
NCT ID NCT05951595
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new triple-drug combination (artemether-lumefantrine-amodiaquine) against standard two-drug treatments for uncomplicated malaria. About 1680 people with malaria will receive one of the treatments and be monitored for 42 days. The goal is to see if the triple therapy works as well or better, especially against drug-resistant malaria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruhuha Health Centre
RECRUITINGRuhuha, Eastern Province, Rwanda
More trials for these conditions
Other studies related to the condition(s) this trial covers.